|
8 Companies |
|
4 Products |
|
4 Products |
|
8 Mechanisms of Action |
|
0 Trials |
|
23 News |
|
- | cyclophosphamide / Generic mfg.
Phase classification, Trial termination, Metastases: Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer (clinicaltrials.gov) - Jan 18, 2019
P1, N=19, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision.
- OPN-7486 / Opna Bio
Trial completion date, Trial termination, Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 21, 2018
P1, N=59, Terminated, Sponsor: Plexxikon
Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision. Trial completion date: Dec 2018 --> Jan 2018 | Active, not recruiting --> Terminated; Discontinued
- AC708 / Daiichi Sankyo
Enrollment change, Trial completion date, Trial termination, Metastases: A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (clinicaltrials.gov) - Mar 21, 2018
P1, N=11, Terminated, Sponsor: Plexxikon
Trial completion date: Dec 2018 --> Jan 2018 | Active, not recruiting --> Terminated; Discontinued N=66 --> 11 | Trial completion date: Apr 2018 --> Jan 2018 | Active, not recruiting --> Terminated; Discontinued
- || OPN-7486 / Opna Bio
Trial primary completion date, Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 6, 2018
P1, N=59, Active, not recruiting, Sponsor: Plexxikon
N=66 --> 11 | Trial completion date: Apr 2018 --> Jan 2018 | Active, not recruiting --> Terminated; Discontinued Trial primary completion date: Dec 2018 --> Jan 2018
- || AC708 / Daiichi Sankyo
Trial primary completion date, Metastases: A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (clinicaltrials.gov) - Dec 19, 2017
P1, N=66, Active, not recruiting, Sponsor: Plexxikon
Trial primary completion date: Dec 2018 --> Jan 2018 Trial primary completion date: Oct 2017 --> Jan 2018
- || OPN-7486 / Opna Bio
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 25, 2017
P1, N=59, Active, not recruiting, Sponsor: Plexxikon
Trial primary completion date: Oct 2017 --> Jan 2018 Recruiting --> Active, not recruiting | N=90 --> 59 | Trial primary completion date: Feb 2021 --> Dec 2018 | Recruiting --> Active, not recruiting | N=90 --> 59 | Trial primary completion date: Feb 2021 --> Dec 2018
- || AC708 / Daiichi Sankyo
Enrollment closed, Metastases: A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (clinicaltrials.gov) - Aug 2, 2017
P1, N=66, Active, not recruiting, Sponsor: Plexxikon
Recruiting --> Active, not recruiting | N=90 --> 59 | Trial primary completion date: Feb 2021 --> Dec 2018 | Recruiting --> Active, not recruiting | N=90 --> 59 | Trial primary completion date: Feb 2021 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Oct 2017 | Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial, Surgery: GCTLIMBS: Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment (clinicaltrials.gov) - Dec 19, 2016
P=N/A, N=412, Completed, Sponsor: Istituto Ortopedico Rizzoli
- || dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Oct 13, 2016
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Oct 2017 | Recruiting --> Active, not recruiting Trial primary completion date: Jun 2015 --> Dec 2016
- || OPN-7486 / Opna Bio
Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 15, 2016
P1, N=90, Recruiting, Sponsor: Plexxikon
Trial primary completion date: Jun 2015 --> Dec 2016 N=160 --> 90
- ||| AC708 / Daiichi Sankyo
Metastases: A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (clinicaltrials.gov) - Mar 4, 2016
P1, N=66, Recruiting, Sponsor: Plexxikon
N=160 --> 90 Not yet recruiting --> Recruiting
- ||| AC708 / Daiichi Sankyo
New P1 trial, Metastases: A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (clinicaltrials.gov) - Feb 4, 2016
P1, N=66, Not yet recruiting, Sponsor: Plexxikon
- || OPN-7486 / Opna Bio
Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 22, 2015
P1, N=160, Recruiting, Sponsor: Plexxikon
Not yet recruiting --> Recruiting N=118 --> 160 | Trial primary completion date: Mar 2017 --> Feb 2021
- zoledronic acid / Generic mfg.
Enrollment change: Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) (clinicaltrials.gov) - May 12, 2015
P2, N=15, Terminated, Sponsor: Leiden University Medical Center
N=118 --> 160 | Trial primary completion date: Mar 2017 --> Feb 2021 N=90 --> 15
- || OPN-7486 / Opna Bio
Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 14, 2015
P1, N=118, Recruiting, Sponsor: Plexxikon
N=90 --> 15 Trial primary completion date: Dec 2014 --> Mar 2017
- ||| dasatinib / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Dec 19, 2014
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Dec 2014 --> Mar 2017 N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015
- || dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Jun 19, 2014
P2, N=502, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- || OPN-7486 / Opna Bio
Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 8, 2013
P1, N=118, Recruiting, Sponsor: Plexxikon
Trial primary completion date: Dec 2013 --> Dec 2014 Initiation date: May 2013 --> Aug 2013
- ||| OPN-7486 / Opna Bio
Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 8, 2013
P1, N=118, Recruiting, Sponsor: Plexxikon
Initiation date: May 2013 --> Aug 2013 Not yet recruiting --> Recruiting
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion: Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) (clinicaltrials.gov) - Apr 14, 2013
P2, N=50, Completed, Sponsor: Centre Leon Berard
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| OPN-7486 / Opna Bio
New P1 trial, Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 3, 2013
P1, N=118, Recruiting, Sponsor: Plexxikon
- zoledronic acid / Generic mfg.
Trial termination: Zometa: Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zom (clinicaltrials.gov) - Jan 29, 2013
P1/2, N=24, Terminated, Sponsor: Nantes University Hospital
Recruiting --> Completed Completed --> Terminated
- zoledronic acid / Generic mfg.
New P1/2 trial: Zometa: Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zom (clinicaltrials.gov) - Mar 25, 2012
P1/2, N=24, Terminated, Sponsor: Nantes University Hospital